Actively Recruiting
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Led by National Institute of Cardiovascular Diseases, Pakistan · Updated on 2026-04-22
1148
Participants Needed
2
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
CONDITIONS
Official Title
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with acute STEMI undergoing primary PCI
- Patients of either sex, 18 years of age or older
You will not qualify if you...
- STEMI patients with cardiogenic shock at presentation
- Patients with heart block
- Allergy to adenosine
- Patients refuse to give consent for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan, 75510
Actively Recruiting
2
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan, 75510
Actively Recruiting
Research Team
M
Muhammad Nauman Khan, FCPS
CONTACT
K
Khalid Naseeb, FCPS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here